Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...

Analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for Sage Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Leerink Partnrs analyst M.

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Truist Financial analyst Joon Lee maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

In a report released today, George Farmer from Scotiabank maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), with a ...

George Baxter has a Ph.D. in organic chemistry, but he was not made for life in the lab. Baxter’s role is expanding the ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...